Paper19463580
Adjuvant radiotherapy after modified Ivor-Lewis esophagectomy: can it prevent lymph node recurrence of the mid-thoracic esophageal carcinoma?
Chen G and 3 others. Ann Thorac Surg, 2009. Cited by 27 papers, by iCite.
Cite this record
ConductScience Library. Adjuvant radiotherapy after modified Ivor-Lewis esophagectomy: can it prevent lymph node recurrence of the mid-thoracic esophageal carcinoma? Papers, record 19463580. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19463580
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Adjuvant radiotherapy after modified Ivor-Lewis esophagectomy: can it prevent lymph node recurrence of the mid-thoracic esophageal carcinoma?
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Squamous Cell | Major topic |
| Esophageal Neoplasms | Major topic |
| Esophagectomy | Major topic |
| Neoplasm Recurrence, Local | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Female | |
| Humans | |
| Lymphatic Metastasis | |
| Male | |
| Middle Aged | |
| Radiotherapy, Adjuvant | |
| Retrospective Studies |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 19463581 | Invited commentary. | https://conductscience.org/library/papers/19463581 |
Source PubMed
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38627783 | A approach of gastric conduit via the anterior of pulmonary hilum route during minimally invasive McKeown esophagectomy. | J Cardiothorac Surg | 2024 | https://conductscience.org/library/papers/38627783 | PubMed |
| 31943824 | Radical esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma followed by adjuvant radiotherapy with or without chemotherapy: Which is more beneficial? | Thorac Cancer | 2020 | https://conductscience.org/library/papers/31943824 | PubMed |
| 30461614 | Comparison of the effect of postoperative radiotherapy with surgery alone for esophagus squamous cell carcinoma patients: A meta-analysis. | Medicine (Baltimore) | 2018 | https://conductscience.org/library/papers/30461614 | PubMed |
| 30050313 | CEP55 promotes the proliferation, migration and invasion of esophageal squamous cell carcinoma via the PI3K/Akt pathway. | Onco Targets Ther | 2018 | https://conductscience.org/library/papers/30050313 | PubMed |
| 28857475 | Overexpression of IFITM3 predicts poor prognosis in stage IIA esophageal squamous cell carcinoma after Ivor Lewis esophagectomy. | Thorac Cancer | 2017 | https://conductscience.org/library/papers/28857475 | PubMed |
| 28243329 | Adjuvant Therapy for a Microscopically Incomplete Resection Margin after an Esophagectomy for Esophageal Squamous Cell Carcinoma. | J Cancer | 2017 | https://conductscience.org/library/papers/28243329 | PubMed |
| 27338033 | Optimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective. | Cancer Res Treat | 2017 | https://conductscience.org/library/papers/27338033 | PubMed |
| 26539332 | Overexpression of IFITM3 predicts the high risk of lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy. | PeerJ | 2015 | https://conductscience.org/library/papers/26539332 | PubMed |
| 26328915 | The impact of adjuvant radiotherapy on radically resected T3 esophageal squamous cell carcinoma. | J Cancer Res Clin Oncol | 2016 | https://conductscience.org/library/papers/26328915 | PubMed |
| 25758053 | Prognostic significance of Ku80 in pT2N0M0 esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy. | Tumour Biol | 2015 | https://conductscience.org/library/papers/25758053 | PubMed |
| 25711486 | Overexpression of Ku80 suggests poor prognosis of locally advanced esophageal squamous cell carcinoma patients. | World J Surg | 2015 | https://conductscience.org/library/papers/25711486 | PubMed |
| 22811814 | Radiation therapy in the postoperative management of esophageal cancer. | J Gastrointest Oncol | 2010 | https://conductscience.org/library/papers/22811814 | PubMed |
| 22700258 | A meta-analysis of lymph node metastasis rate for patients with thoracic oesophageal cancer and its implication in delineation of clinical target volume for radiation therapy. | Br J Radiol | 2012 | https://conductscience.org/library/papers/22700258 | PubMed |
| 22591456 | Gastric tube resection due to metachronic cancer and a recurrence in anastomosis after Ivor-Lewis esophagectomy--case report. | World J Surg Oncol | 2012 | https://conductscience.org/library/papers/22591456 | PubMed |
| 19842230 | Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. | World J Gastroenterol | 2009 | https://conductscience.org/library/papers/19842230 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19463580
GET https://conductscience.org/api/papers/v1/19463580/authors